A Decade of Transformation in Melanoma Treatments

Source: Targeted Oncology, May 2022

Ongoing and proposed melanoma research will naturally continue to evaluate new treatment types.

When Keith T. Flaherty began treating patients with advanced melanoma 2 decades ago, his recommendation was simple: If you’re eligible, enroll in a clinical trial.

As late as 2010, only 2 FDA-approved therapies existed for the treatment of advanced melanoma: the chemotherapy dacarbazine and high-dose (HD) IL-2. A review of 3 dacarbazine trials reported response rates of 10% to 15% and overall survival (OS) of 8 months.1 An analysis of HD IL-2 treatment reported a response rate of 16% and severe toxicity but also a durable response rate of just under 5% of patients.